EGAGenomicsCancer Genomicshttps://ega-archive.org/studies/EGAS00001005464EGAEGA study EGAS00001005464Genomic data of acute myeloid leukemia from the NGS-PTL european consortiumEGArestrictedother disease, scale tissue, Biological Markers, Viral Marker, Plays, Surrogate Endpoints, determination, Clinical Markers, Laboratory, acute non lymphoblastic leukemia, Myeloid, Clinical Marker, peltate hair, STK10, Biochemical, Endpoint, Cost Comparisons, Measure, Serum, Cost-Minimization, Surrogate End Points, Surrogate Markers, Aneuploidies, Laboratory Markers, Structural, acute non lymphoblastic leukaemia, diseases, Cost Minimization Analysis, Roles, Biological, Functional, leukaemia NOS, disease or disorder, Concepts, diseases and disorders, acute myeloid, Analysis, Leucocythaemia, Cost Comparison, leukaemia, Toy, acute myeloid leukaemia (AML), Aneuploid Cell, Runx-1, Biomarker, human disease, Leukemia, Clinical, Analyses, Playthings, Aneuploid, Cost Measures, Comparative Genomics, Cost-Minimization Analyses, Affordability, plant peltate hair, Acute Myeloblastic Leukemia, Biological Marker, bases, Basen, Measures, Leucocythemias, Comparison, aml1., financing, amlcr1, pebp2ab, Fast, non-neoplastic, genetic, XAML, Cost Analysis, funding, Aneuploid Cells, Immunologic Markers, Immune, Puppets, Markers, ATP:Fas-activated serine/threonine protein phosphotransferase activity, Clients, Viral Markers, Role Concepts, Therapies, Play, disorder, Homo sapiens disease, ANLL, Comparisons, Affordabilities, constitutitional genetic, Immunologic Marker, FAST, Puppet, Biologic, acute myelogenous, leukemia, Therapy, fees, Aneuploids, Genomics, Viral, Surrogate Endpoint, Nucleobase, Comparative, Serum Markers, disorders, familial, End Point, FASTK, Biochemical Markers, medical condition, Functional Genomics, Biologic Marker, Client, Leukemias, Cell, Immune Marker, Concept, AML, Role Concept, Playthings and Play, Marker, Surrogate End Point, Base2, chemical analysis, Base1, Diseases, Role, Plaything, condition, scales, aml1-evi-1, cbfa2, evi-1, finances, Leucocythaemias, Costs and Cost Analyses, Biologic Markers, aml, Costs, Acute myelogenous leukemia, Leucocythemia, Serum Marker, scale, End Points, Myeloblastic, Surrogate, Xaml1, Cost, susceptibility to, Endpoints, Toys, Cost-Minimization Analysis, salaries, Acute Myeloid Leukemia, Pricing, Immunologic, Laboratory Marker, Treatments, Surrogate Marker, disease, cost, Acute, Patient, Therapeutic, acute myeloid leukemia (AML), Biochemical Marker, Base, Cells, aml-1, Structural Genomics, Treatment, inherited genetic, nucleobases, assay, financial management, Cost Measure, hereditary, Cost Analyses, base, Immune MarkersMyelogenous Leukemias, Myelocytic, Therapy, leukemia, Myelogenous, Acute Myeloblastic, acute myeloblastic leukemia, M1, M2, acute myelogenous leukemia, Nonlymphocytic Leukemia, acute non lymphoblastic leukemia, Myeloid, acute myeloblastic leukaemia, acute myelogenous leukaemia, Myelocytic Leukemia, Leukemias, Acute Myeloid, Acute Myelocytic Leukemias, AML, Acute Myelocytic Leukemia, Nonlymphoblastic Leukemia, Nonlymphocytic Leukemias, Nonlymphoblastic, acute non lymphoblastic leukaemia, Acute Myeloid Leukemias, M1., Myeloid Leukemias, leukaemia NOS, Acute Myelocytic, Acute Nonlymphoblastic, acute myeloid, Leucocythaemia, Acute Nonlymphocytic, leukaemia, Myeloblastic Leukemia, Acute Myelogenous Leukemia, Leucocythaemias, treatment, acute, Acute myelogenous leukemia, Leucocythemia, Leukemia, Myeloblastic, Acute Myelogenous, Acute Myeloblastic Leukemia, susceptibility to, Myeloblastic Leukemias, Acute Myeloid Leukemia, Leucocythemias, acute myeloid leukemia, acute myeloid leukaemia, Myelogenous Leukemia, Acute Nonlymphocytic Leukemias, Nonlymphocytic, Treatments, Acute Myeloid Leukemia without Maturation, Acute Myeloid Leukemia with Maturation, Acute, Acute Nonlymphoblastic Leukemia, Therapeutic, Acute Nonlymphocytic Leukemia, Acute Nonlymphoblastic Leukemias, Acute Myeloblastic Leukemias, disease management, Myeloid Leukemia, Acute Myelogenous Leukemias, Myelocytic Leukemias, Therapies, Treatment, ANLL, Nonlymphoblastic Leukemias, AML - acute Myeloid Leukemia, acute myelogenousfalseNext Generation Sequencing platform for targeted Personalized Therapy of Leukemia - Acute myeloid leukemiaThe advent of high-throughput next generation sequencing (NGS) technologies that are revolutionizing genomics and transcriptomics by providing a single base resolution tool for a unified deep analysis of diseases complexity allows a fast and cost-efficient fine-scale assessment of the genetic variability hidden within cohorts of patients affected by the same leukemia. That being so, by potentially highlighting inter-individual differences that may play a role in the differential success of diverse therapeutic interventions, they promise to be crucial for selecting the most appropriate medical treatments. The project aims at the identification of novel prognostic biomarkers for acute myeloid leukemia (AML) and studied the molecular differences between aneuploid and euploid AML.2021-08-11 08:37:13EGAS000010054649606EGAD00001007940EGAC00001002223